Flavivirus neutralizing antibodies and methods of use thereof
The present invention provides antibodies that neutralize flavivirus and methods of use thereof. These antibodies are derived from mAb1 1 which recognizes West Nile virus E protein and is cross-reactive with members of the flavivirus family, including Denge virus. The antibodies of the present invention prevent antibody-dependent enhancement of a viral infection by having a modified Fc region that does not bind to the Fcy receptor. The invented antibody is used to treat flaviviral infections and symptoms thereof.
1. An isolated humanized monoclonal antibody comprising:
(i) a heavy chain with three CDRs comprising the amino acid sequences GYSTH (SEQ ID NO: 21), WDNPSSGDTTYAENFRG (SEQ ID NO:22), and GGDDYSFDH (SEQ ID NO: 23) respectively;
(ii) a light chain with three CDRs comprising the amino acid sequences RGDSLRSYYAS (SEQ ID NO:24), GENNRPS (SEQ ID NO:25), and NSRDSSDHLLL (SEQ ID NO: 26) respectively; and
(iii) a modified Fc region having mutations at amino acid positions 234 and 235, such that the Fc region does not bind to an Fcγ receptor, wherein
(a) the mutations are L234A and L235A wherein position 234 and 235 corresponds to positions 240 and 241 of SEQ ID NO:20; and
(a) the antibody binds and neutralizes a flavivirus.
2. The antibody of claim 1 , wherein the Fc region comprises the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 13.
3. An isolated humanized monoclonal antibody comprising:
(i) a heavy chain with three CDRs comprising the amino acid sequences GYSTH (SEQ ID NO: 21), WDNPSSGDTTYAENFRG (SEQ ID NO:22), and GGDDYSFDH (SEQ ID NO: 23) respectively;
(ii) a light chain with three CDRs comprising the amino acid sequences RGDSLRSYYAS (SEQ ID NO:24), GENNRPS (SEQ ID NO:25), and NSRDSSDHLLL (SEQ ID NO: 26) respectively; and
(iii) an Fc region comprising the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 13
wherein the antibody binds and neutralizes a flavivirus.
4. The antibody of claim 1 or 3 , wherein said antibody does not contribute to an antibody-dependent enhancement of a flavivirus infection.
5. The antibody of claim 1 or 3 , wherein the modified Fc region binds to the neonatal Fc receptor.
6. The antibody of claim 1 or 3 , wherein the flavivirus is West Nile virus, Dengue virus (serotypes 1-4), St. Louis encephalitis virus, yellow fever virus, Japanese encephalitis virus, or Murray Valley encephalitis virus.
7. The antibody of claim 1 or 3 , wherein said humanized monoclonal antibody is produced in a plant.
8. The antibody of claim 1 or 3 linked to a therapeutic agent.
9. The antibody of claim 8 , wherein said therapeutic agent is a toxin, a radiolabel, a siRNA, a small molecule, or a cytokine.
10. The antibody of claim 9 , wherein said cytokine is TGF-beta.
11. An isolated cell that produces the antibody of claim 1 .
12. The isolated cell of claim 11 , wherein said isolated cell is a plant cell.
13. A method of reducing antibody-dependent enhancement of a flavivirus infection comprising administering an effective amount of the antibody of claim 1 or 3 to a subject.
14. The method of claim 13 , wherein said antibody is administered after a first infection by a flavivirus.
15. A method of increasing vaccine efficiency comprising administering to a subject an effective amount of antibody according to claim 1 or 3 and a vaccine.
16. The method of claim 15 , wherein said antibody and said vaccine are administered sequentially or concurrently.
17. The method of claim 15 , wherein said vaccine is a viral vaccine.
18. A method of treating or alleviating a symptom of a flavivirus infection, comprising administering to a subject in need thereof an effective amount of a composition comprising an antibody according to claim 1 or 3 .
19. A method of delaying the onset of one or more symptoms of a flavivirus infection, comprising administering to a subject in need thereof an effective amount of a composition comprising an antibody according to claim 1 or 3 .
20. The method of claim 18 , further comprising administering an anti-viral agent.
21. The method of claim 20 , wherein the anti-viral agent is an antibody, an antibody linked to a therapeutic agent, or a small molecule.
22. The method of claim 20 , wherein said antibody and the anti-viral agent are administered sequentially or concurrently.
23. The method of claim 18 , wherein said one or more symptom comprises weight loss, paralysis, fever, headache, nausea, vomiting, skin rash, and body aches.
24. The method of claim 18 , wherein said flavivirus is West Nile virus, Dengue virus (serotypes 1-4), St. Louis encephalitis virus, yellow fever virus, Japanese encephalitis virus, or Murray Valley encephalitis virus.